Affinivax, Inc.

• BrainChild Bio, a spin-out from Seattle Children's Hospital, is set to advance CAR-T cell therapies for central nervous system (CNS) tumors, with an initial focus on pediatric brain tumors. • The company's lead CAR-T cell therapy has already been evaluated in nearly 100 children, building upon clinical testing at Seattle Children's, and plans to present results at a scientific meeting next year. • BrainChild Bio will optimize CAR-T therapies for CNS tumors using a next-generation platform, incorporating multiplex targeting and enhanced potency controls to prevent tumor escape and minimize toxicities. • With initial funding from Seattle Children's, BrainChild Bio plans to pursue accelerated approval for DIPG and extend its therapies to adult glioblastoma and brain metastases, led by CEO Steve Brugger.

Affinivax, Inc.

Seattle Children's Spin-Out, BrainChild Bio, Aims to Revolutionize CAR-T Therapy for Pediatric Brain Tumors